Camden National Bank raised its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 9.3% in the fourth quarter, HoldingsChannel reports. The firm owned 5,029 shares of the company’s stock after buying an additional 427 shares during the period. Camden National Bank’s holdings in Eli Lilly And Co were worth $581,000 as of its most recent SEC filing.
Other hedge funds have also made changes to their positions in the company. Ironwood Financial llc bought a new stake in Eli Lilly And Co during the 4th quarter valued at $30,000. Csenge Advisory Group bought a new stake in Eli Lilly And Co during the 3rd quarter valued at $58,000. Cornerstone Advisors Inc. grew its stake in shares of Eli Lilly And Co by 21.3% in the 3rd quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock worth $83,000 after acquiring an additional 136 shares in the last quarter. Atwood & Palmer Inc. grew its stake in shares of Eli Lilly And Co by 267.0% in the 4th quarter. Atwood & Palmer Inc. now owns 734 shares of the company’s stock worth $85,000 after acquiring an additional 534 shares in the last quarter. Finally, First Command Bank grew its stake in shares of Eli Lilly And Co by 31.3% in the 4th quarter. First Command Bank now owns 834 shares of the company’s stock worth $96,000 after acquiring an additional 199 shares in the last quarter. Institutional investors and hedge funds own 80.84% of the company’s stock.
Several analysts have recently issued reports on LLY shares. Barclays reiterated a “buy” rating and issued a $130.00 target price on shares of Eli Lilly And Co in a research note on Sunday, January 20th. BMO Capital Markets upped their target price on shares of Eli Lilly And Co from $124.00 to $132.00 and gave the stock an “outperform” rating in a research note on Monday, December 24th. They noted that the move was a valuation call. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b+” rating in a research note on Tuesday, November 6th. UBS Group started coverage on shares of Eli Lilly And Co in a research note on Wednesday, January 23rd. They issued a “buy” rating and a $131.00 target price for the company. Finally, Wolfe Research started coverage on shares of Eli Lilly And Co in a research note on Tuesday, October 23rd. They issued a “market perform” rating and a $119.00 target price for the company. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $111.41.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 195,000 shares of the company’s stock in a transaction dated Monday, November 19th. The shares were sold at an average price of $115.31, for a total transaction of $22,485,450.00. Following the sale, the insider now directly owns 118,505,584 shares of the company’s stock, valued at $13,664,878,891.04. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 817,843 shares of company stock valued at $94,595,335. 0.11% of the stock is owned by company insiders.
LLY opened at $119.65 on Thursday. The stock has a market cap of $125.67 billion, a P/E ratio of 21.56, a P/E/G ratio of 1.91 and a beta of 0.37. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. Eli Lilly And Co has a fifty-two week low of $74.51 and a fifty-two week high of $121.84.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). The company had revenue of $6.44 billion for the quarter, compared to the consensus estimate of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 42.55%. Eli Lilly And Co’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.14 EPS. Analysts predict that Eli Lilly And Co will post 5.6 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be given a dividend of $0.645 per share. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $2.58 annualized dividend and a yield of 2.16%. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio is presently 40.54%.
TRADEMARK VIOLATION NOTICE: This report was reported by Highlight Press and is owned by of Highlight Press. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://highlightpress.com/2019/02/14/camden-national-bank-acquires-427-shares-of-eli-lilly-and-co-lly.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.